Share
The pharma industry briefing
The latest news, approvals and clinical trials you need to know about this month
Data:
News
in Numbers
200,000
Gilead has agreed to donate HIV medication for up to 200,000 people each year for up to 11 years
$2bn
The value of unproven cellular therapies according to a recent ProPublica and New Yorker report
$2m
The potential price tag of Novartis’ new gene therapy drug, Zolgensma
2030
Indian officials have vowed to eliminate malaria by 2030
100
Human lifespan could soon pass 100 years thanks to medical tech, according to Bank of America analysts
Data:
News
in Numbers
200,000
Gilead has agreed to donate HIV medication for up to 200,000 people each year for up to 11 years
$2bn
The value of unproven cellular therapies according to a recent ProPublica and New Yorker report
2030
Indian officials have vowed to eliminate malaria by 2030
$2m
The potential price tag of Novartis’ new gene therapy drug, Zolgensma
100
Human lifespan could soon pass 100 years thanks to medical tech, according to Bank of America analysts
UK Government funds plans for 'pay as you go' drug development AI
In the UK, a government initiative has funnelled a small amount of cash into two organisations—Chief.AI and the Medicines Discovery Catapult—in an effort to make AI accessible to all drug discovery researchers and help nudge the UK bioscience sector into the future.
Source: Fierce Biotech
Cannabinoid-based drug discovery and development is about to get an upgrade
Tetra Bio-Pharma, engaged in cannabinoid-based drug discovery & development, recently acquired Panag Pharma, creating a new strategic partnership delving further into the cannabis industry.
Source: Health Europa
Pfizer acquires Therachon and its dwarfism drug
Pfizer has announced it will pay $340m upfront to snap up rare disease biotech Therachon, which is developing treatments for a form of dwarfism and short bowel syndrome (SBS).
Source: Pharmaphorum
Erectile dysfunction drug 'effective' as heart failure treatment
A drug used to treat erectile dysfunction has been found to slow or even reverse the progression of heart failure in sheep. The study is a breakthrough in the treatment for the disease in which five year survival rates are lower than most common cancers.
Source: Science Daily
AstraZeneca blood cancer drug hits study goal early
A Phase III trial testing AstraZeneca's Calquence in previously treated chronic lymphocytic leukemia will be stopped early, after an interim analysis found patients on the blood cancer therapy were doing significantly better than those receiving one of two combination regimens containing the commonly used drug Rituxan.
Source: Bio Pharma Dive
Approvals
Ruzurgi (amifampridine)
The US Food and Drug Administration (FDA) has approved Ruzurgi tablets for the treatment of Lambert-Eaton myasthenic syndrome in patients 6 to less than 17 years of age.
Source: FDA
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis)
On May 3, the (FDA) approved Vyndaqel and Vyndamax capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults.
Source: FDA
Ocrevus (ocrelizumab)
Patients with a severe progressive form of multiple sclerosis will get access to the first licensed treatment for the condition after NICE recommended regular NHS funding for Roche’s Ocrevus, although there are still restrictions on who will receive it.
Source: Pharmaphorum
Dengvaxia
The FDA has approved the first vaccine for dengue, Dengvaxia, but placed significant restrictions on its use because the vaccine has been shown to put some people at heightened risk for a severe form of the disease.
Source: New York Times
Go to top
Go to top
Share this article
